Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-18T20:47:42.293Z Has data issue: false hasContentIssue false
  • English
  • Français

Can medication management review reduce anticholinergic burden (ACB) in the elderly? Encouraging results from a theoretical model

Published online by Cambridge University Press:  20 June 2013

Zikai He  and
Patrick Anthony Ball
Zikai He*
Affiliation:
School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales 2650, Australia
Patrick Anthony Ball
Affiliation:
School of Psychological and Clinical Sciences, Charles Darwin University, Casuarina Campus, Darwin, Northern Territory 0909, Australia
*
Correspondence should be addressed to: Zikai He, School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales 2650, Australia. Phone: +61-425-780-775. Email: [email protected].
Get access

Abstract

Background:

Review of recent journal articles and various relevant current textbooks provides strong evidence to show that anticholinergic burden is a material issue in frail and at-risk patients. This study assesses the anticholinergic burden in a group of patients in residential care facilities and then applies a theoretical intervention model. It is based on a scoring system known as the Anticholinergic Cognitive Burden (ACB) scale, and attempts to reduce the anticholinergic burden while maintaining therapeutic benefits.

Methods:

A database of 691 patients was analyzed for each individual's ACB based on the scale of scoring produced by groups of experts in the area. A theoretical intervention was then conducted using relevant, evidence-based practice guidelines for clinical therapeutics in Australia. The intervention had the aim of reducing the total ACB without affecting the apparent intended effectiveness of the prescribed therapy.

Results:

Of the 35% (n = 242) patients who score at least 1 point on the ACB, a reduction is achievable in 59% of the cases. In particular, the reduction from a clinically significant score of 3 or above to 2 or below for 49 of those patients is possible in 85% of the cases. Overall, this represents a reduction from 7.10% to 1.01% for the entire population. It is also found that of the 246,960 counts of items dispensed (both prescription and non-prescription) for these patients, 47,334 (or 19.2%) of these were of agents on the ACB scale.

Conclusions:

The study found that it appears to be possible that the total ACB of a group of 691 patients can be significantly reduced.

Keywords

ACBanticholinergic agentsanticholinergicscognitive burdenreduction
Type
Research Article
Information
International Psychogeriatrics , Volume 25 , Issue 9 , September 2013 , pp. 1425 - 1431
Copyright
Copyright © International Psychogeriatric Association 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abe, S., Chiba, K., Cirincione, B., Grasela, T. H., Ito, K. and Suwa, T. (2009). Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. The Journal of Clinical Pharmacology, 49, 1071–1078.CrossRefGoogle ScholarPubMed
Agar, M., Currow, D., Plummer, J., Seidel, R., Carnahan, R. and Abernethy, A. (2009). Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliative Medicine, 23, 257–265.CrossRefGoogle ScholarPubMed
AMH. (2012). Australian Medicines Handbook 2012. Adelaide, Australia: Australian Medicines Handbook.Google Scholar
Boustani, M., Campbell, N., Munger, S., Maidment, I. and Fox, C. (2008). Impact of anticholinergics on the aging brain: a review and practical application. Aging Health Aging Health, 4, 311–320.CrossRefGoogle Scholar
Carnahan, R. M., Lund, B. C., Perry, P. J., Pollock, B. G. and Culp, K. R. (2006). The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. The Journal of Clinical Pharmacology, 46, 1481–1486.CrossRefGoogle ScholarPubMed
Davis, D. H. J., Rockwood, M. R. H., Mitnitski, A. B. and Rockwood, K. (2011). Impairments in mobility and balance in relation to frailty. Archives of Gerontology and Geriatrics, 53, 79–83.CrossRefGoogle ScholarPubMed
Desborough, J.et al. (2011). Multi-professional clinical medication reviews in care homes for the elderly: study protocol for a randomised controlled trial with cost effectiveness analysis. Trials, 12, 218–226.CrossRefGoogle ScholarPubMed
Fox, C.et al. (2011). Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. Journal of the American Geriatrics Society, 59, 1477–1483.CrossRefGoogle ScholarPubMed
Hori, K.et al. (2011). Influence of anticholinergic activity in serum on clinical symptoms of Alzheimers disease. Neuropsychobiology, 63, 147–153.CrossRefGoogle Scholar
Hutchison, L. C. and O’Brien, C. E. (2007). Changes in pharmacokinetics and pharmacodynamics in the elderly patient. Journal of Pharmacy Practice, 20, 4–12.CrossRefGoogle Scholar
Krum, H. and Teerlink, J. R. (2011). Heart failure 2: medical therapy for chronic heart failure. The Lancet, 378, 713–721.CrossRefGoogle Scholar
Kuluris, B. (2007). General Practice and State Mental Health Services, Barwon Health (ed.). Victoria, Australia: Barwon Health, Victorian Government.Google Scholar
Maidment, I. D., Fox, C., Boustani, M. and Katona, C. (2012). Medication management – the missing link in dementia interventions. International Journal of Geriatric Psychiatry, 27, 439–442.CrossRefGoogle ScholarPubMed
MIMS Australia. (2012). MIMS Online [Online]. Available at: http://ezproxy.csu.edu.au/login?url=http://dx.doi.org/5230001_2; last accessed 15 March 2012. (CMPMedica, Sydney, Australia).Google Scholar
Minton, J. A., Tofade, T. S. and Shah, S. A. (2009). Psychosis from anticholinergic medications administered at a smoking cessation clinic. Journal of Pharmacy Practice, 22, 489–493.CrossRefGoogle Scholar
Neurology Expert Group. (2010). Therapeutic Guidelines Complete. North Melbourne, Australia: Therapeutic Guidelines.Google Scholar
Nishtala, P. S.et al. (2009). Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. The Journal of Clinical Pharmacology, 49, 1176–1184.CrossRefGoogle ScholarPubMed
Rockwood, K. K. (2005). What would make a definition of frailty successful? Age and Ageing, 34, 432–434.CrossRefGoogle ScholarPubMed
Rockwood, K. and Mitnitski, A. (2007). Frailty in relation to the accumulation of deficits. The Journals of Gerontology, 62A, 722–727.Google Scholar
Rockwood, K. K. and Mitnitski, A. A. (2011). Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clinics in Geriatric Medicine, 27, 17–26.CrossRefGoogle ScholarPubMed
Rockwood, K., Song, X. and Mitnitski, A. (2011). Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ: Canadian Medical Association Journal, 183, E487–E494.CrossRefGoogle ScholarPubMed
Ronaldson, K. J., Fitzgerald, P. B., Taylor, A. J., Topliss, D. J. and McNeil, J. J. (2011). A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. The Australian and New Zealand Journal of Psychiatry, 45, 458–465.CrossRefGoogle Scholar
Sittironnarit, G.et al. (2011). Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dementia and Geriatric Cognitive Disorders, 31, 173–178.CrossRefGoogle ScholarPubMed
Spinewine, A., Schmader, K. E., Barber, N. and Hughes, C. (2007). Prescribing in elderly people 1: appropriate prescribing in elderly people: how well can it be measured and optimised? The Lancet, 370, 173–184.CrossRefGoogle Scholar
Tune, L., Carr, S., Hoag, E. and Cooper, T. (1992). Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. The American Journal of Psychiatry, 149, 1393–1394.Google ScholarPubMed
Wawruch, M.et al. (2012). The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoepidemiology and Drug Safety, 21, 170–176.CrossRefGoogle ScholarPubMed